Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-cash Items (2016 - 2018)

Historic Non-cash Items for Vanda Pharmaceuticals (VNDA) over the last 9 years, with Q1 2018 value amounting to $3.3 million.

  • Vanda Pharmaceuticals' Non-cash Items fell 8461.36% to $3.3 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.3 million, marking a year-over-year decrease of 8461.36%. This contributed to the annual value of $3.5 million for FY2017, which is 8908.94% down from last year.
  • According to the latest figures from Q1 2018, Vanda Pharmaceuticals' Non-cash Items is $3.3 million, which was down 8461.36% from $3.5 million recorded in Q4 2017.
  • In the past 5 years, Vanda Pharmaceuticals' Non-cash Items registered a high of $37.4 million during Q3 2017, and its lowest value of $3.3 million during Q1 2018.
  • For the 5-year period, Vanda Pharmaceuticals' Non-cash Items averaged around $17.7 million, with its median value being $15.0 million (2015).
  • In the last 5 years, Vanda Pharmaceuticals' Non-cash Items soared by 164135.0% in 2014 and then plummeted by 8908.94% in 2017.
  • Over the past 5 years, Vanda Pharmaceuticals' Non-cash Items (Quarter) stood at $28.5 million in 2014, then plummeted by 73.71% to $7.5 million in 2015, then skyrocketed by 332.82% to $32.5 million in 2016, then plummeted by 89.09% to $3.5 million in 2017, then dropped by 6.13% to $3.3 million in 2018.
  • Its Non-cash Items stands at $3.3 million for Q1 2018, versus $3.5 million for Q4 2017 and $37.4 million for Q3 2017.